Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06847464 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
A Phase 1 study of RSV Infection and Drug-Drug Interaction (DDI), sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT06847464 is a Phase 1 study of RSV Infection and Drug-Drug Interaction (DDI) that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 48 participants, below the 741-participant average among 8 other RSV Infection trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06847464, a Phase 1 study of RSV Infection and Drug-Drug Interaction (DDI), has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of the study is to assess the effect of itraconazole, carbamazepine, quinidine, and fluconazole individually on the pharmacokinetics and safety of EDP-323 in healthy adult participants. Each participant's duration in the study will be dependent upon which study part they are enrolled.
Conditions Studied
Interventions
- DRUG Itraconazole
- DRUG carbamazepine
- DRUG EDP-323
Study Locations (1)
Texas
- ICON, plc - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-01-27 |
| Est. Completion | 2025-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06847464
The ClinicalTrials.gov registry entry for NCT06847464 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 741-participant average among 8 other RSV Infection trials with a reported enrollment target (94% lower). The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with RSV Infection appearing as the primary indexed condition, and to 3 interventions - of which Itraconazole is the first listed.
NCT06847464 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06847464 about?
NCT06847464 is a clinical study titled "A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.". The primary aim of the study is to assess the effect of itraconazole, carbamazepine, quinidine, and fluconazole individually on the pharmacokinetics and safety of EDP-323 in healthy adult participants. Each participant's duration in the study will be dependent upon which study part they are enrolled...
What is the current status of trial NCT06847464?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-01-27. Estimated completion is 2025-06-01.
What conditions does trial NCT06847464 study?
This clinical trial studies the following conditions: RSV Infection, Drug-Drug Interaction (DDI).
What interventions are being tested in trial NCT06847464?
The interventions under investigation include: Itraconazole (DRUG), carbamazepine (DRUG), EDP-323 (DRUG).
Who is sponsoring clinical trial NCT06847464?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06847464 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RSV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
RECRUITING · Phase 1
-
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
COMPLETED · Phase 1
-
A Study of EDP-323 in Healthy Subjects
COMPLETED · Phase 1
-
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
RECRUITING · Phase 3
-
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
RECRUITING
-
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.